山东科源制药股份有限公司

Group 1 - The company plans to issue shares and pay cash to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 39 trading parties, including its controlling shareholder, Linuo Investment Holding Group Co., Ltd. [5][6] - The transaction constitutes a related party transaction as several of the trading parties are identified as related parties under the Shenzhen Stock Exchange's rules [6] - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3]